Urological Cancer

Clinical trials for patients with cancer of the urinary tract or male reproductive system. This includes cancers found in the kidney, ureter, bladder, prostate, testes or penis.

If you would like to be considered for a clinical trial you will require a referral from your current treating team. Visit the Joining a Clinical Trial page for referral information. 

For more information on clinical trials, get in contact with our cancer clinical trials enquiry coordinator.

Clinical Trials Enquiry Coordinator

Business hours, Mon to Friday between 9am - 2pm
Email [email protected]
Phone (03) 8559 7456

Open and Recruiting Clinical Trials

Title

A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castrationresistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy

Trial ID

NCT03834519

Cancer type

Prostate cancer

Status

Open and recruiting

Phase

Three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to what is available for that cancer type.

Brief summary

A clinical trial to test if the treatment Pembrolizumab given with Olaparib is safe and better than the standard treatment given (Vandetanib or Enzalutamide) for patients with prostate cancer that has spread to other parts of the body.

Pembrolizumab is a type of treatment called immunotherapy, which works with your immune system to help stop cancer cells growing. Pembrolizumab has been effective in other cancer types and is now being tested to see if it is effective and safe in the treatment of prostate cancer when given with Olaparib. This combination will be compared against the standard treatment given for prostate can that has spread to other parts of the body and has rising PSA levels. Patients will be randomly selected to receive one of the following:

Arm 1: Pembrolizumab in combination with olaparib

Arm 2: Abiraterone acetate and prednisone/prednisolone (if you have been previously treated with enzalutamide) or enzalutamide (if you have been previously treated with abiraterone acetate).

Who can participate

Men who:

  • Have cancer that has spread to other parts of the body
  • Have had treatment for their prostate cancer but it has gotten worse or has not responded to treatment given for their cancer
  • Are able to swallow medication by mouth

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial. 

For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.

Title

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer

Trial ID

NCT03748641

Cancer type

Prostate Cancer

Status

Open and recruiting

Phase

Three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to what is available for that cancer type.

Brief summary

A clinical trial to test if the treatment Niraparib given together with abiraterone acetate and Prednisolone is better than abiraterone acetate and Prednisolone given alone in men with prostate cancer that has spread to other parts of the body.

Niraparib works by stopping certain cancer cells from being able to repair themselves when damaged. Prednisone is a type of drug called a corticosteroid. Prednisone is given with abiraterone acetate to reduce or stop some of the side effects of abiraterone acetate. Abiraterone acetate in combination with prednisone is approved for the treatment of prostate cancer. It is believed that Niraparib given with abiraterone acetate and Prednisolone will stop the cancer from growing and improve outcomes for patients.

Patients will be randomly selected and will receive one of the following:

Part 1: Niraparib given with abiraterone acetate and Prednisolone

Part 2: Placebo (a pill/liquid that contains no treatment) given with abiraterone acetate and prednisolone

Who can participate

Men who:

  • Have received treatment for their cancer but it has gotten worse or not responded to the treatment given for their cancer
  • Have prostate cancer that has spread to other parts of the body

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial. 

For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.

Title

Phase 1 trial of 177Lu-PSMA-617 therapy and Olaparib in patients with Metastatic Castrate Resistant Prostate Cancer (LuPARP)

Trial ID

NCT03874884

Cancer type

Prostate cancer that has spread to other parts of the body

Status

Open and recruiting

Phase

One: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one is to test the safety of the new treatment and find the best dose to give patients.

Brief summary

A clinical trial to test the safety and effectiveness of the treatment Olaparib given together with a type of radiation therapy, 177Lu-PSMA-617, in men with prostate cancer that has spread to other parts of the body.

Olaparib is a type of treatment called PARP inhibitor, which works by stopping PARP proteins in the body that repair damaged cancer DNA. When given with radiation therapy, Olaparib works to stop the body repairing the radiation therapy damage to the cancer DNA. 177Lu-PSMA-617 is a type of precision radiation therapy that works by targeting a type of protein called PSMA (prostate specific membrane antigen) found on the surface of prostate cancer cells. If the prostate cancer has spread to other parts of the body, the PSMA will also be present in those areas. 177Lu-PSMA will use radiation to try to destroy all cancer cells that are expressing PSMA in various parts of your body.

It is believed that this new treatment combination may be able to kill more prostate cancer cells and control the cancer for longer periods.

Who can participate

Men who

  • Have had treatment for their cancer but it has gotten worse or has not responded to the treatment given
  • Have prostate cancer that has spread to other parts of their body
  • Have prostate cancer that is able to be targeted by the 177Lu-PSMA

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial. 

For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.

Title

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-life Extended Bispecific T-cell Engager AMG 160 in Subjects With Metastatic Castration-resistant

Trial ID

NCT03792841

Cancer type

Prostate cancer

Status

open and recruiting

Phase

One: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one is to test the safety of the new treatment and find the best dose to give patients.

Brief summary

A clinical trial to find the best dose of the new treatment AMG160 and test if it is safe and effective in treating men with prostate cancer that has spread to other parts of the body. AMG160 will be given alone or in combination with the treatment Pembrolizumab. AMG160 and Pembrolizumab are types of treatment called immunotherapy, which works with your immune system to help find and stop cancer cells growing.

Who can participate

Men who:

  • Have had treatment for their prostate cancer but it has gotten worse or has not responded to treatment given for their cancer
  • Have prostate cancer that has spread to other parts of the body

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.

Title

A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer

Trial ID

NCT04446117

Cancer type

Prostate cancer

Status

Opening Soon

Phase

Three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to what is available for that cancer type.

Brief summary

A clinical trial to test the safety and effectiveness of treatment Cabozantinib given with a type of immunotherapy (Atezolizumab) compared to Novel Hormonal Therapy (NHT) in patients with prostate cancer that has spread to other parts of the body.

The aim of this clinical trial is to test if the treatment Cabozantinib given with Atezolizumab is better than a second course of NHT for treating patients with prostate cancer that has spread to other parts of the body. Cabozantinib is a type of treatment that targets genetic changes which can help cancer grow. Atezolizumab is type of treatment called immunotherapy, which works with your immune system to help stop cancer cells growing. It is expected this combination will work together to help the body’s immune system to kill the cancer. Patients will be randomly selected to receive on into one of two treatment arms:

Arm 1: Cabozantinib and atezolizumab

Arm 2: NHT (Abiraterone and prednisone or enzalutamide)

Who can participate

Patients who:

  • Have cancer that has spread to other parts of the body
  • Have received prior treatment with (NHT)

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.

Title

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Trial ID

NCT04497844

Cancer type

Prostate cancer

Status

Opening Soon

Phase

Three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to what is available for that cancer type

Brief summary

The aim of this clinical trial is to test if Niraparib given with standard treatment (Abiraterone acetate and Prednisone) is better than the standard treatment given alone in treating men with prostate cancer that has spread outside of the prostate area and to other parts of the body. Niraparib is a type of treatment that works by stopping certain cancer cells from being able to repair themselves from damage, which is expected to kill the cancer cells.

Patients will be randomly selected to receive one of the following:

Arm 1: Niraparib plus abiraterone acetate and prednisolone or

Arm 2: Placebo plus abiraterone acetate and prednisolone

This is a double-blinded clinical trial, which means you and your clinical trial doctor will not know which treatment you are receiving.

Who can participate

Patients who:

  • Have cancer that can not be removed through surgery
  • Have cancer that has spread outside of the prostate that can be treated by lowering testosterone levels in the body
  • Have cancer that has spread to other parts of the body
  • Have been treated with immunotherapy before

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.

Title

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Delta-like Protein 3 Half-life Extended Bispecific T-cell Engager AMG 757 in Subjects with De Novo or Treatment Emergent Neuroendocrine Prostate Cancer

Trial ID

NCT04702737

Cancer type

Neuroendocrine prostate cancer

Status

Opening soon

Phase

One: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one is to test the safety of the new treatment and find the best dose to give patients.

Brief summary

The aim of the clinical trial is to test the safety and effectiveness of new treatment AMG757 in treating neuroendocrine prostate cancer. AMG 757 is a type of treatment that works with the body’s natural defence system to destroy prostate cancer cells. The clinical trial has two parts, the first will find the best dose of AMG757, the second will test AMG757 in a larger group of patients to further test the safety and effectiveness of the treatment.

Who can participate

Patients who:

  • Have cancer that has spread to other parts of their body

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.

Title

A randomised phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castrate-resistant prostate cancer treated with enzalutamide

Trial ID

NCT04419402

Cancer type

Prostate cancer

Status

Open and recruiting

Phase

Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types

Brief summary

A clinical trial to test if the treatment Lutetium-177 PSMA (Lu-PSMA) given with Enzalutamide is better than Enzalutamide given alone in treating men with prostate cancer that has spread to other parts of the body and has grown despite previous hormone treatment.

Enzalutamide is an approved treatment for this cancer type. The clinical trial will test if the addition of Lu-PSMA will improve outcomes in the treatment of prostate cancer that has spread to other parts of the body and has grown despite previous hormone treatment. Lu-PSMA is a type of precision radiation therapy that works by targeting a type of protein called PSMA (prostate specific membrane antigen) found on the surface of prostate cancer cells. If the prostate cancer has spread to other parts of the body, the PSMA will also be present in those areas. Lu-PSMA will use radiation to try to destroy all cancer cells that are expressing PSMA. Enzalutamide works by stopping the growth of cancer cells. It is expected this new treatment combination may be able to kill more prostate cancer cells.

Arm 1: Enzalutamide given with Lu-PSMA

Arm 2: Enzalutamide given alone

Both patients and doctors will know which arm of treatment they are receiving.

Who can participate

Men who:

  • Have cancer that has spread to other parts of the body and has grown despite previous hormone treatment
  • Have not been treated for prostate cancer since it has spread to other parts of the body
  • Have not had a seizure before

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.

Title

A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Trial ID

NCT04191096

Cancer type

Prostate cancer

Status

Open and recruiting

Phase

Three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to what is available for that cancer type.

Brief summary

A clinical trial to test the safety and effectiveness of the treatment combination Pembrolizumab given with Enzalutamide and the hormone treatment Androgen Deprivation Therapy (ADT) for men with prostate cancer that has spread outside of the prostate and has not gotten worse on hormone therapy.

The aim of the clinical trial is to test the safety and effectiveness of the treatment combination and if it is better than Enzalutamide and ADT given alone. The clinical trial will also test if this combination will improve patients quality of life.

Pembrolizumab is a type of treatment called immunotherapy, which works with your immune system to help stop cancer cells growing. Enzalutamide works by stopping the growth of cancer cells. ADT is a type of anti-hormone treatment used to treat prostate cancer. Prostate cancer cells usually require androgen hormones (like testosterone) to grow. ADT works by reducing the levels of androgen hormones, to prevent the prostate cancer cells from growing.

Patients will be randomly selected to receive either of the following:

Arm 1: Pembrolizumab given with Enzalutamide and ADT

Arm 2: Enzalutamide given with ADT

Who can participate

Men who:

  • Have cancer that has spread outside of the prostate
  • Have cancer that has not gotten worse on hormone therapy

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.

Title

UpFrontPSMA: A randomised phase 2 study of sequential 177 Lu-PSMA617 and docetaxel versus docetaxel in metastatic Hormone-Naïve prostate Cancer

Trial ID

NCT04343885

Cancer type

Prostate cancer

Status

Open and recruiting

Phase

Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types.

Brief summary

A trial to see if the treatment Lutetium-177 PSMA (Lu-PSMA) given with and Docetaxel is better than Docetaxel alone for men with prostate cancer that has spread to other parts of the body and not been treated with hormone therapy.

Lu-PSMA is a type of precision radiation therapy that works by targeting a type of protein called PSMA (prostate specific membrane antigen) found on the surface of prostate cancer cells. If the prostate cancer has spread to other parts of the body, the PSMA will also be present in those areas. Lu-PSMA will use radiation to try to destroy all cancer cells that are expressing PSMA. Docetaxel is a type of chemotherapy that works by stopping cells from growing and multiplying.

Lu-PSMA and Docetaxel are proven to be effective in treating prostate cancer that has spread, it is expected that this combination may improve treatment outcomes.

Patients will also be given Androgen Deprivation Therapy (ADT). ADT is a type of anti-hormone treatment used to treat prostate cancer. Prostate cancer cells usually require androgen hormones (like testosterone) to grow. ADT works by reducing the levels of androgen hormones, to prevent the prostate cancer cells from growing.

Patient will be randomly selected to receive one of the following:

Arm 1: Lu-PSMA given with Docetaxel and ADT

Arm 2: Docetaxel given with ADT

Both patients and their doctor will know what treatment arm they are receiving.

Who can participate

Men who:

  • Have cancer that has spread to other parts of the body
  • Have not been treated with hormone therapy

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.

Title

Registry-based Study of Enzalutamide vs Abiraterone assessing cognitive function in ELderly patients with Metastatic Castration-Resistant Prostate Cancer

Trial ID

ACTRN12620000463976

Cancer type

Prostate cancer

Status

Open and recruiting

Phase

Use from below

Brief summary

The aim of this clinical trial is to test the cognitive impact (the ability to think, learn and memorise) of two standard treatments (Abiraterone and Enzalutamide) for prostate cancer that has spread to other parts of the body, while taking into account the effectiveness and other side effects of these treatments.

Abiraterone and Enzalutamide are effective in controlling prostate cancer when used either as the first treatment or after the chemotherapy agent Docetaxel. Cognitive changes are a significant concern among older patients. Both Abiraterone and Enzalutamide are often used in older patients but the effect of these treatments on cognition is not well understood.

Patients on clinical trial will be randomly selected to receive either of the following:

Arm 1: Abiraterone, tablet taken by mouth daily

Arm 2: Enzalutamide, tablet taken by mouth daily

Both arms will continue on treatment until their doctor decides they should stop.

As part of this clinical trial, patients will answer questionnaires about their ability to think, learn and memorise (cognition), their mood status and their risk of falling.

It is expected this clinical trial will clarify if one of these medications has less of an impact on cognitive decline, mood or falls risk, which may help doctors in the decision of what medication to use for elderly patients in the future.

Who can participate

Men who:

  • Aged 75 or over
  • Have cancer that has spread outside the prostate
  • Are eligible for PBS-subsidised treatment with Abiraterone or Enzalutamide
  • Are suitable to receive full dose therapy
  • Are able to complete telephone interviews
  • Are able to take oral medications

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.

Title

A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours

Trial ID

NCT02582697

Cancer type

Testicular germ cell cancer

Phase

Three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to what is available for that cancer type.

Brief summary

A clinical trial to test if giving BEP (Bleomycin given with Etoposide and Cisplatin) chemotherapy every three weeks is better than giving BEP chemotherapy every two weeks in men with testicular germ cell cancer.

The current standard treatment given for testicular germ cell cancer is a chemotherapy combination called BEP (Bleomycin given with Etoposide and Cisplatin), given every 3 weeks. BEP is given with a treatment called Pegfilgrastim or Filgrastim which stimulates white blood cell production.The aim of this clinical trial is to test if giving the same amount of BEP every 2 weeks is better than every 3 weeks and if the side effects can be well tolerated.

Patients will be randomly selected to receive one of the following:

Arm 1: BEP chemotherapy every 21 days

Arm 2: BEP chemotherapy every 14 days

Who can participate

Men who:

  • Have a germ cell cancer
  • Have not been treated for their cancer before

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.

Title

A Randomised Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilising Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory

Trial ID

ACTRN12618001236280

Cancer type

Germ Cell Tumours

Status

Open and recruiting

Phase

Three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to what is available for that cancer type.

Brief summary

A clinical trial to test the safety and effectiveness of high dose chemotherapy compared to standard dose chemotherapy in men with testicular germ cell cancer.

High dose chemotherapy and standard dose chemotherapy are both effective treatments for testicular germ cell cancer. The aim of the clinical trial is to test which treatment is better.

Patients will be randomly selected to receive one of the following:

Arm 1: 4 cycles standard dose chemotherapy with Paclitaxel, Ifosfamide, Cisplatin, and Pegfilgrastim or Filgrastim

Arm 2: 2 cycles standard dose paclitaxel and Ifosfamide with Pegfilgrastim or Filgrastim. Followed by 3 cycles of high dose of Carboplatin and Etoposide with a stem cell transplant after each cycle.

Stem cell transplant helps the immune system to be restored after the high dose chemotherapy.

Who can participate

Men who:

  • Have testicular germ cell cancer
  • Have been treated for their cancer once before

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial. 

For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.

Title

A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Abberations

Trial ID

NCT03390504

Cancer type

Urothelial bladder cancer with changes in the genes of the cancer

Status

Open and recruiting

Phase

Three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to what is available for that cancer type.

Brief summary

A clinical trial to test if the treatment Erdafitinib is better than different types of chemotherapy and immunotherapy for patients with urothelial bladder cancer with changes in the genes of the cancer.

The clinical trial will test the effects of Erdafitinib compared to other treatments already used to treat bladder cancer (chemotherapy: Docetaxel or Vinfluine and immunotherapy: Pembrolizumab). Erdafitinib is a type of treatment that targets a group of proteins called FGFR (fibroblast growth factor receptors), commonly present in bladder cancer cells. Genetic changes in FGFR may contribute to the development of bladder cancer. Erdafitinib has shown effective in treating other cancer types with these genetic changes. Patient will be FGFR gene changes will be suitable for this trial.

Patients will be randomly selected to receive one of the following:

Arm 1: Erdafitinib

Arm 2: Chemotherapy (Docetaxel)

Arm 3: Chemotherapy (Vinflunine)

Arm 4: Immunotherapy (Pembrolizumab)

They will not be able to choose which treatment they have.

Who can participate

Patients who:

  • Have bladder cancer with specific genetic changes (FGFR gene changes)
  • Have cancer that has spread to other parts of the body
  • Have cancer that is not able to be removed through surgery
  • Have received treatment for bladder cancer but it has gotten worse or has not responded to treatment given for their cancer
  • Do not have cancer that has spread to the brain

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial. 

For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial registry.

Title

A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions

Trial ID

NCT04172675

Cancer type

Non-muscle-invasive bladder cancer

Status

Open and recruiting

Phase

Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types.

Brief summary

A clinical trial to test the safety and effectiveness of the treatment Erdafitinib in patients with a type of bladder cancer called non-muscle-invasive bladder cancer that has come back after treatment with Bacillus Calmette-Guerin (BCG). The aim of this clinical trial is to test the effectiveness of the treatment Erdafitinib and if it’s better than treatment with Chemotherapy.

Erdafitinib is a type of treatment that targets a group of proteins called FGFR (fibroblast growth factor receptors), commonly present in bladder cancer cells. Genetic changes in FGFR may contribute to the development of bladder cancer. Erdafitinib has shown effective in treating other cancer types with these genetic changes. Patient with FGFR gene changes will be suitable for this trial.

Patients on clinical trial will receive either of the following:

Arm 1: Erdafitinib

Arm 2: Chemotherapy

Patients will know which treatment they are on.

Who can participate

Patients who:

  • Have cancer with FGFR genetic changes.
  • Have already received Bacillus Calmette-Guérin (BCG) treatment and their cancer has gotten worse

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.

Title

A Phase 1/1b first-in-human dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of SAR439459 administered intravenously as monotherapy and in combination with cemiplimab in adult patients with advanced solid tumors

Trial ID

NCT03192345

Cancer type

Bladder cancer

Status

Opening and recruiting

Phase

One: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one is to test the safety of the new treatment and find the best dose to give patients.

Brief summary

A clinical trial to test the safety and effectiveness of new treatment SAR439459 given alone or with Cemiplimab, in patients with bladder cancer.

SAR439459 is a type of treatment called anti-TGFβ that works by blocking the effects of a molecule in the body called transforming growth factor beta (or TGFβ). TGFβ has many effects in the body and is often over-produced in solid cancers, such as bladder and colon cancer. Over produced TGFβ can help cancer grow, spread and avoid being attacked by the bodies immune system. SAR439459 may help treat the cancer by blocking TGFβ's effects on cancer growth. Cemiplimab is a type of treatment called immunotherapy, which works with your immune system to help stop cancer cells growing. The combination of treatments is expected to work together by improving the body’s immune response to cancer.

Who can participate

Patients who:

  • Have cancer that has spread to other part of their body
  • have not been treated with immunotherapy
  • Do not have some eye problems
  • Are not taking medication to thin their blood

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.

Title

A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9 Engineered T Cells (CTX130) in Adult Subjects with Unresectable or Metastatic Renal Cell Carcinoma (RCC) with predominantly clear cell differentiation

Trial ID

NCT04438083

Cancer type

Renal cell cancer

Status

Open and recruiting

Phase

One/two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to test for the new treatment to find the best dose and find effective in these cancer types.

Brief summary

A clinical trial of new modified T cell therapy, CTX130 in patients with renal cell cancer that has come back or got worse after receiving treatment for the cancer.

The aim of this clinical trial is to test the safety and efficacy of treatment CTX130 in patients with renal cell carcinoma. CTX130 is a type of treatment known as modified T cell therapy. The T cells are collected from another person’s blood (donor) and modified using a type of technology called CRISPR/Cas9. The clinical trial will find the best dose of a new treatment and test how effective it works on renal cell cancer.

Who can participate

Patients who:

  • Have had treatment for their cancer but it has gotten worse or not responded to previous treatment
  • Do not have cancer that has spread to their brain

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.

Title

A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Combination with Axitinib in Subjects with Advanced Renal Cell Carcinoma

Trial ID

NCT02493751

Cancer type

Advanced renal cell cancer also known as kidney cancer

Status

Opening Soon

Phase

One: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one is to test the safety of the new treatment and find the best dose to give patients.

Brief summary

The aim of this clinical trial is to test the safety and efficacy of the treatment combination (MEDI5752 given with Axtinib) for patients with advanced kidney cancer. MEDI5752 is a type of treatment that works by helping the body’s immune system find and kill cancer cells. Axtinib works to slow cancer growth and can help the cancer to shrink.

The clinical trial has two parts, the first will find the best dose of MEDI5752 to use with Axtinib and the second will test MEDI5752 given with Axtinib in a larger group of patients to further test the safety and effectiveness of the treatment combination.

Who can participate

Patients who:

  • Have not received treatment for their cancer since it has gotten worse

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.